人乳头瘤病毒检测方法研究进展
|
摘要
人乳头瘤病毒(Human papilloma viruses,HPV)是少数几种明确与人类癌症相关的病毒之一,其持续感染是导致宫颈癌发生的重要危险因素。HPV的检测对宫颈癌的筛查及治疗宫颈病变药物的有效性评价有重要作用,因此国内外对HPV的检测方法不断革新。纵观近年来HPV检测方法,主要依赖于分子生物技术检测HPV的DNA、RNA、癌蛋白等,但各种检测方法的原理、适用范围及临床意义均不相同。本文将就目前常用的HPV检测技术及试剂盒进行简要介绍,并对各方法的优缺点、灵敏度及特异性进行分析,以期为临床选择合适的检测方法提供参考。
Human papilloma virus(HPV) is one of the few viruses explicitly related to human cancers, and persistent HPV infection is a major risk factor for cervical cancer. The detection of HPV plays an important role in screening cervical cancer and evaluating the effectiveness of drugs for the treatment of cervical lesions. Therefore, the methods for detection of HPV have been constantly innovated at home and abroad. In recent years, HPV detection methods mainly rely on molecular biotechnology that detect HPV DNA, HPV RNA and oncoprotein, etc. However, the principles, applicable scope and clinical significance of various detection methods are different. This paper will briefly introduce the currently commonly used techniques and kits for HPV detection, and analyze the pros and cons, sensitivity and specificity of each method, in order to provide references for clinical selection of suitable HPV detection methods.
Human papilloma virus(HPV) is one of the few viruses explicitly related to human cancers, and persistent HPV infection is a major risk factor for cervical cancer. The detection of HPV plays an important role in screening cervical cancer and evaluating the effectiveness of drugs for the treatment of cervical lesions. Therefore, the methods for detection of HPV have been constantly innovated at home and abroad. In recent years, HPV detection methods mainly rely on molecular biotechnology that detect HPV DNA, HPV RNA and oncoprotein, etc. However, the principles, applicable scope and clinical significance of various detection methods are different. This paper will briefly introduce the currently commonly used techniques and kits for HPV detection, and analyze the pros and cons, sensitivity and specificity of each method, in order to provide references for clinical selection of suitable HPV detection methods.
引文
[1] de Sanjosé S,Brotons M,Pavón MA.The natural history of human papillomavirus infection[J].Best Pract Res Clin Obstet Gynaecol,2017,47:2-13.
[2] Panczyszyn A,Boniewska-Bernacka E,G?ab G.Telomeres and telomerase during human papillomavirus-induced carcinogenesis[J].Mol Diagn Ther,2018,22(4):421-430.
[3] Berti FCB,Pereira APL,Cebinelli GCM,et al.The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma[J].Cytokine Growth Factor Rev,2017,34:1-13.
[4] Mattoscio D,Medda A,Chiocca S.Human papilloma virus and autophagy[J].Int J Mol Sci,2018,19(6).pii:E1775.
[5] Bogani G,Leone Roberti Maggiore U,Signorelli M,et al.The role of human papillomavirus vaccines in cervical cancer:prevention and treatment[J].Crit Rev Oncol Hematol,2018,122:92-97.
[6] Martínez-Ramírez I,Carrillo-García A,Contreras-Paredes A,et al.Regulation of cellular metabolism by high-risk human papillomaviruses[J].Int J Mol Sci,2018,19(7).pii:E1839.
[7] Humphrey P,Bennett C,Cramp F.The experiences of women receiving brachytherapy for cervical cancer:a systematic literature review[J].Radiography(Lond),2018,24(4):396-403.
[8] Yang A,Farmer E,Wu TC,et al.Perspectives for therapeutic HPV vaccine development[J].J Biomed Sci,2016,23(1):75.
[9] Iftner T,Neis KJ,Castanon A,et al.The longitudinal clinical performance of the RNA-based AHPV human papillomavirus(HPV) assay in comparison to the DNA-based hybrid capture 2 HPV test in 2 consecutive screening rounds with a 6-year interval in Germany[J].J Clin Microbiol,2019,57(1).pii:e01177-18.
[10] Hooper JE,Hebert JF,Schilling A,et al.Hybrid capture 2 is as effective as PCR testing for high risk human papillomavirus in head and neck cancers[J].Appl Immunohistochem Mol Morphol,2015,23(4):266-272.
[11] Ki EY,Lee YK,Lee A,et al.Comparison of the PANArray HPV genotyping chip test with the cobas 4800 HPV and Hybrid capture 2 tests for detection of HPV in ASCUS women[J].Yonsei Med J,2018,59(5):662-668.
[12] Yin D,Jiang Y,Wang N.The diagnostic value of serum hybrid capture 2(CH2) HPV DNA in cervical cancer:a systematic review and meta-analysis[J].Tumour Biol,2014,35(9):9247-9253.
[13] Koliopoulos G,Nyaga VN,Santesso N.Cytology versus HPV testing for cervical cancer screening in the general population[J].Cochrane Database Syst Rev,2017,8:CD008587.
[14] Karimi Zarch M,Heydari E,Tabatabaie A,et al.Diagnostic value of care TM HPV test in screening for cervical intraepithelial neoplasia grade 2 or worse[J].Asian Pac J Cancer Prev,2017,18(3):687-693.
[15] Bottari F,Boveri S,Iacobone AD,et al.Transition from hybrid capture 2 to Cobas 4800 in Hpv detection:sensitivity and specificity for CIN2+ in two time periods[J].Infect Dis(Lond),2018,50(7):554-559.
[16] Tranberg M,Jensen JS,Bech BH.Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the Cobas 4800 HPV DNA test[J].BMC Infect Dis,2018,18(1):348.
[17] Stoler MH,Wright TC Jr,Parvu V,et al.The onclarity human papillomavirus trial:design,methods,and baseline results[J].Gynecol Oncol,2018,149(3):498-505.
[18] Nakamura M,Nakade K,Orisaka S,et al.Comparison study of BD onclarity HPV with digene HC2 high-risk HPV DNA test and Roche Cobas 4800 HPV for detecting high-risk human papillomavirus in Japan[J].Am J Clin Pathol,2019,151(3):263-269.
[19] Wong AK,Chan RC,Nichols WS,et al.Human papillomavirus(HPV) in atypical squamous cervical cytology:the Invader HPV test as a new screening assay[J].J Clin Microbiol,2008,46(3):869-875.
[20] Munson E,Du Chateau,BK,Bellerose,B,et al.Clinical laboratory evaluation of Invader? chemistry and hybrid capture for detection of high-risk human papillomavirus in liquid-based cytology specimens[J].Diagn Microbiol Infect Dis,2011,71(3):230-235.
[21] Alaghehbandan R,Fontaine D,Bentley J,et al.Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology[J].Diagn Cytopathol,2013,41(9):767-775.
[22] Wang HY,Lee D,Park S.Diagnostic performance of HPV E6/E7 mRNA and HPV DNA assays for the detection and screening of oncogenic human papillomavirus infection among woman with cervical lesions in China[J].Asian Pac J Cancer Prev,2015,16(17):7633-7640.
[23] Tewari P,White C,Kelly L,et al.Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities[J].Diagn Cytopathol,2018,46(12):987-992.
[24] Arbyn M,Roelens J,Cuschieri K,et al.The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology:a meta-analysis of the diagnostic accuracy[J].Int J Cancer,2013,132(1):101-108.
[25] Duvlis S,Popovska-Jankovic K,Arsova ZS,et al.HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women[J].J Med Virol,2015,87(9):1578-1586.
[26] Ewaisha R,Panicker G,Maranian P,et al.Serum immune profiling for early detection of cervical disease[J].Theranostics,2017,7(16):3814-3823.
[27] Venuti A,Paolini F.HPV detection methods in head and neck cancer[J].Head Neck Pathol,2012,6(Suppl 1):S63-74.
[28] Ressler S,Scheiden R,Dreier K,et al.High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma[J].Clin Cancer Res,2007,13(23):7067-7072.
[29] Stiasny A,Kuhn C,Mayr D,Kost B,et al.Immunohistochemical evaluation of E6/E7 HPV oncoproteins staining in cervical cancer[J].Anticancer Res,2016,36(6):3195-3198.
[30] Lidqvist M,Nilsson O,Holmgren J,et al.Detection of human papillomavirus oncoprotein E7 in liquid-based cytology[J].J Gen Virol,2012,93(Pt 2):356-363.
[31] Krings A,Dückelmann AM,Moser L,et al.Performance of OncoE6 cervical test with collection methods enabling self-sampling[J].BMC Womens Health,2018,18(1):68.
[32] Verachi F,Percario Z,Di Bonito P,et al.Purification and characterization of antibodies in single-chain format against the E6 oncoprotein of human papillomavirus type 16[J].Biomed Res Int,2018,2018:6583852.
[33] Martins VA,Pinho JD,Teixeira Júnior AAL,et al.P16INK4a expression in patients with penile cancer[J].PLoS One,2018,13(10):e0205350.
[2] Panczyszyn A,Boniewska-Bernacka E,G?ab G.Telomeres and telomerase during human papillomavirus-induced carcinogenesis[J].Mol Diagn Ther,2018,22(4):421-430.
[3] Berti FCB,Pereira APL,Cebinelli GCM,et al.The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma[J].Cytokine Growth Factor Rev,2017,34:1-13.
[4] Mattoscio D,Medda A,Chiocca S.Human papilloma virus and autophagy[J].Int J Mol Sci,2018,19(6).pii:E1775.
[5] Bogani G,Leone Roberti Maggiore U,Signorelli M,et al.The role of human papillomavirus vaccines in cervical cancer:prevention and treatment[J].Crit Rev Oncol Hematol,2018,122:92-97.
[6] Martínez-Ramírez I,Carrillo-García A,Contreras-Paredes A,et al.Regulation of cellular metabolism by high-risk human papillomaviruses[J].Int J Mol Sci,2018,19(7).pii:E1839.
[7] Humphrey P,Bennett C,Cramp F.The experiences of women receiving brachytherapy for cervical cancer:a systematic literature review[J].Radiography(Lond),2018,24(4):396-403.
[8] Yang A,Farmer E,Wu TC,et al.Perspectives for therapeutic HPV vaccine development[J].J Biomed Sci,2016,23(1):75.
[9] Iftner T,Neis KJ,Castanon A,et al.The longitudinal clinical performance of the RNA-based AHPV human papillomavirus(HPV) assay in comparison to the DNA-based hybrid capture 2 HPV test in 2 consecutive screening rounds with a 6-year interval in Germany[J].J Clin Microbiol,2019,57(1).pii:e01177-18.
[10] Hooper JE,Hebert JF,Schilling A,et al.Hybrid capture 2 is as effective as PCR testing for high risk human papillomavirus in head and neck cancers[J].Appl Immunohistochem Mol Morphol,2015,23(4):266-272.
[11] Ki EY,Lee YK,Lee A,et al.Comparison of the PANArray HPV genotyping chip test with the cobas 4800 HPV and Hybrid capture 2 tests for detection of HPV in ASCUS women[J].Yonsei Med J,2018,59(5):662-668.
[12] Yin D,Jiang Y,Wang N.The diagnostic value of serum hybrid capture 2(CH2) HPV DNA in cervical cancer:a systematic review and meta-analysis[J].Tumour Biol,2014,35(9):9247-9253.
[13] Koliopoulos G,Nyaga VN,Santesso N.Cytology versus HPV testing for cervical cancer screening in the general population[J].Cochrane Database Syst Rev,2017,8:CD008587.
[14] Karimi Zarch M,Heydari E,Tabatabaie A,et al.Diagnostic value of care TM HPV test in screening for cervical intraepithelial neoplasia grade 2 or worse[J].Asian Pac J Cancer Prev,2017,18(3):687-693.
[15] Bottari F,Boveri S,Iacobone AD,et al.Transition from hybrid capture 2 to Cobas 4800 in Hpv detection:sensitivity and specificity for CIN2+ in two time periods[J].Infect Dis(Lond),2018,50(7):554-559.
[16] Tranberg M,Jensen JS,Bech BH.Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the Cobas 4800 HPV DNA test[J].BMC Infect Dis,2018,18(1):348.
[17] Stoler MH,Wright TC Jr,Parvu V,et al.The onclarity human papillomavirus trial:design,methods,and baseline results[J].Gynecol Oncol,2018,149(3):498-505.
[18] Nakamura M,Nakade K,Orisaka S,et al.Comparison study of BD onclarity HPV with digene HC2 high-risk HPV DNA test and Roche Cobas 4800 HPV for detecting high-risk human papillomavirus in Japan[J].Am J Clin Pathol,2019,151(3):263-269.
[19] Wong AK,Chan RC,Nichols WS,et al.Human papillomavirus(HPV) in atypical squamous cervical cytology:the Invader HPV test as a new screening assay[J].J Clin Microbiol,2008,46(3):869-875.
[20] Munson E,Du Chateau,BK,Bellerose,B,et al.Clinical laboratory evaluation of Invader? chemistry and hybrid capture for detection of high-risk human papillomavirus in liquid-based cytology specimens[J].Diagn Microbiol Infect Dis,2011,71(3):230-235.
[21] Alaghehbandan R,Fontaine D,Bentley J,et al.Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology[J].Diagn Cytopathol,2013,41(9):767-775.
[22] Wang HY,Lee D,Park S.Diagnostic performance of HPV E6/E7 mRNA and HPV DNA assays for the detection and screening of oncogenic human papillomavirus infection among woman with cervical lesions in China[J].Asian Pac J Cancer Prev,2015,16(17):7633-7640.
[23] Tewari P,White C,Kelly L,et al.Clinical performance of the Cobas 4800 HPV test and the Aptima HPV assay in the management of women referred to colposcopy with minor cytological abnormalities[J].Diagn Cytopathol,2018,46(12):987-992.
[24] Arbyn M,Roelens J,Cuschieri K,et al.The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology:a meta-analysis of the diagnostic accuracy[J].Int J Cancer,2013,132(1):101-108.
[25] Duvlis S,Popovska-Jankovic K,Arsova ZS,et al.HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women[J].J Med Virol,2015,87(9):1578-1586.
[26] Ewaisha R,Panicker G,Maranian P,et al.Serum immune profiling for early detection of cervical disease[J].Theranostics,2017,7(16):3814-3823.
[27] Venuti A,Paolini F.HPV detection methods in head and neck cancer[J].Head Neck Pathol,2012,6(Suppl 1):S63-74.
[28] Ressler S,Scheiden R,Dreier K,et al.High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma[J].Clin Cancer Res,2007,13(23):7067-7072.
[29] Stiasny A,Kuhn C,Mayr D,Kost B,et al.Immunohistochemical evaluation of E6/E7 HPV oncoproteins staining in cervical cancer[J].Anticancer Res,2016,36(6):3195-3198.
[30] Lidqvist M,Nilsson O,Holmgren J,et al.Detection of human papillomavirus oncoprotein E7 in liquid-based cytology[J].J Gen Virol,2012,93(Pt 2):356-363.
[31] Krings A,Dückelmann AM,Moser L,et al.Performance of OncoE6 cervical test with collection methods enabling self-sampling[J].BMC Womens Health,2018,18(1):68.
[32] Verachi F,Percario Z,Di Bonito P,et al.Purification and characterization of antibodies in single-chain format against the E6 oncoprotein of human papillomavirus type 16[J].Biomed Res Int,2018,2018:6583852.
[33] Martins VA,Pinho JD,Teixeira Júnior AAL,et al.P16INK4a expression in patients with penile cancer[J].PLoS One,2018,13(10):e0205350.